ANTI-ANGIOGENIC MIMETICS FOR CANCER THERAPY

用于癌症治疗的抗血管生成模拟物

• 批准号: 6287887
• 负责人: JEFFREY A GREENSPAN
• 金额: $ 25万
• 依托单位: MUNIN CORPORATION
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-08-15 至 2002-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6287887
• 关键词: Sf9 cell line; angiogenesis factor; angiogenesis inhibitors; antineoplastics; biological products; biomimetics; biotechnology; biotherapeutic agent; cell growth regulation; cell migration; drug design /synthesis /production; drug screening /evaluation; laboratory rat; neoplastic growth; peptide chemical synthesis; protein purification; synthetic peptide

DESCRIPTION: (Applicant's Description) Angiogenesis, formation of new blood vessels, is essential for progressive tumor growth and metastasis. Therapies aimed at inhibiting tumor angiogenesis (and shrinking tumors through nutrient starvation) hold great promise in cancer treatment, because they avoid two of the major problems associated with standard chemotherapy, i.e., the eventual growth of chemotherapy-resistant tumors and the debilitating systemic side effects engendered by chemotherapy. In particular, the rational design of biological agents that specifically suppress the angiogenic activity of tumor-promoting factors in the body is potentially an excellent means of creating such novel therapeutic agents. The specific aims of phase I of this proposal are 1) to generate and purify likely candidate biological agents that may specifically suppress the tumor angiogenic and tumor promoting activities of a particular angiogenic factor that is strongly implicated as an essential regulator of tumor growth, and 2) to screen these agents in a live animal model for their ability to block the angiogenic activity of the targeted factor. Agents identified as suppressors of the targeted factor's angiogenic activity would be tested in Phase II for their ability to suppress and/or regress the tumor growth-promoting activity of the targeted factor, and those that are able to do so would be developed further as clinical anti-cancer agents. PROPOSED COMMERCIAL APPLICATION: Cancer is the second leading cause of mortality in the U.S., and its health care costs are well over $100 billion. Solid tumors comprise the majority of cancers, afflict over 3 million people, and cause over a half million deaths annually. The health care market for anti- angiogenesis anti-cancer agents is very significant because conventional chemotherapy selects for resistant cancer cells, and causes significant toxicity to normal tissue.

描述：（申请人的描述） 血管生成，即新血管的形成，对于进行性进展至关重要 肿瘤生长和转移。 旨在抑制肿瘤血管生成的疗法 （以及通过营养饥饿缩小肿瘤）在 癌症治疗，因为它们避免了与癌症相关的两个主要问题 标准化疗，即化疗耐药性的最终增长 肿瘤和化疗引起的使人衰弱的全身副作用。 特别是生物制剂的合理设计 抑制体内肿瘤促进因子的血管生成活性 可能是创造此类新型治疗剂的绝佳方法。 这 该提案第一阶段的具体目标是 1) 生成和纯化可能的 可能特异性抑制肿瘤的候选生物制剂 特定血管生成因子的血管生成和肿瘤促进活性 与肿瘤生长的重要调节因子密切相关，2) 在活体动物模型中筛选这些药物的阻断能力 目标因子的血管生成活性。 被确定为抑制剂的药剂 目标因子的血管生成活性将在第二阶段进行测试 它们抑制和/或消退肿瘤生长促进活性的能力 目标因素，以及那些有能力做到这一点的因素将被开发 进一步作为临床抗癌药物。 拟议的商业应用： 癌症是美国第二大死亡原因，其医疗费用高达 远远超过1000亿美元。 实体瘤占癌症的大部分，影响超过 300 万人 人，每年造成超过 50 万人死亡。 抗击医疗保健市场 血管生成抗癌剂非常重要，因为常规化疗 选择耐药癌细胞，并对正常组织造成显着毒性。